Main Session: Overview of Immunotherapy

What are the mechanisms of action and adverse effects of these agents?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA

Related Material

Is programmed cell death ligand 1 (PD-L1) testing necessary?

When should you image patients to assess response to immunotherapy?

Why is pseudo-progression an important issue in patients on immune checkpoint inhibitors?

How do responses to immune checkpoint inhibitors differ from responses to chemotherapy?

What cancers are most likely to respond to immunotherapy?

How do you educate patients about the timing of early and latent side effects?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.